the aid library

LIST OPTIONS

Filter

5687

Retention and mortality outcomes from a community-supported public–private HIV treatment programme in Myanmar

Mburu, Gitau; Aung Zayar Paing; Nwe Ni Myint et al. (2016) CC

Journal of the International AIDS Society 2016, 19:20926
There is a growing interest in the potential contribution the private sector can make towards increasing access to antiretroviral therapy (ART) in low‐ and middle‐income settings. This article describes a public–private partnership ... more

Download (365)

View PDF (775)

Disability-inclusive social protection research in Nepal

Banks, Lena M., Walsham, Matthew and others International Centre for Evidence in Disability (2018) C1

A national overview with a case study from Tanahun district. The overall aims of this study are (1) to assess the extent to which social protection systems in Nepal address the needs of people with disabilities; and (2) to identify and document elements of good practice, as well as challenges, in th... more

Download (458)

View PDF (620)

Rwanda: MOH GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF HUMAN PHARMACEUTICAL PRODUCTS

Ministry of Health, Rwanda (2014) C2

These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M... more

Download (351)

View PDF (561)

Money & Microbes: Strengthening clinical research capacity to prevent epidemics

International Vaccines Task Force (IVTF) (2018) C1

Robust clinical research capacity in low- and middle-income countries is key to stemming the spread of epidemics, according to a new report from the International Vaccines Task Force (IVTF). The report lays out how to develop the political support, financing and coordination required to build this c... more

Download (901)

View PDF (950)

Untangling the Web of Antiretroviral Price Reductions. 18th edition

MSF Access Campaign Médecins Sans Frontières (2016) C3

This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand... more

Download (107)

View PDF (172)

Belgian Antibiotic Policy Coordination Committee Policy paper for the 2014-2019 term

Erica Balligand, Michiel Costers and Evelyne Van Gastel Belgian Antibiotic Policy Coordination Committee (2014) C2

Antimicrobial resistance represents a big threat to public health. The Centers for Disease Control and Prevention (CDC) estimate that every year two million Americans are infected with a (multi-)drug resistant bacterium, resulting in 23,000 deaths. The WHO has repeatedly drawn attention to this majo... more

Download (109)

View PDF (168)

Supporting survivors of violence with a multi-sectorial, solidarity-based, stress- and trauma-sensitive approach

Karin Griese, Alena mehlau Medica Mundiale (2016) CC

Guiding the work of medica mondiale is an attitude of sensitivity towards both trauma and stress. This stress- and trauma-sensitive approach has a strengthening and relieving effect on the affected people and also the activists, specialist staff and working groups. For medica mondiale, trauma as a... more

Download (140)

View PDF (212)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. fir... more

Download (135)

View PDF (184)

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
recommended

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc... more

Download (205)

View PDF (189)

Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine

World Health Organization WHO (2022) C_WHO

6 June 2022 These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. Th... more

Download (116)

View PDF (145)

WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment

World Health Organization WHO (2020) C_WHO

The 2020 recommendations for the programmatic management of TB preventive treatment are the first to be released under the rubric of WHO consolidated TB guidelines (Module 1 – Prevention). The WHO consolidated TB guidelines will gradually group all TB recommendations and will be complemented by ma... more

Download (369)

View PDF (338)

The South African Triage Scale (SATS), Training Manual

Western Cape Government (2012) C1

The aim of the SATG was to produce a triage scale for use throughout South Africa. The group was multi-disciplinary and comprised doctors, nurses and paramedics. The result of the SATG’s activities is the South African Triage Scale (SATS), a physiology and symptom based scale which prioritises int... more

Download (136)

View PDF (286)

Integration of HIV testing and linkage in family planning and contraception services: implementation brief

World Health Organisation (WHO) (2021) C_WHO

This implementation brief addresses integration of HIV testing services into family planning (FP) services. It is intended as a practical resource for national health programmes seeking to introduce or scale up HIV testing and linkage to HIV prevention, sexually transmitted infection, and antiretrov... more

Download (202)

View PDF (196)

State of inequality: HIV, tuberculosis and malaria.

World Health Organization WHO; Global Fund (2021) C_WHO

The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria are part of a group of agencies working together to accelerate progress towards the health-related SDGs through the Global Action Plan for Healthy Lives and Well-being for All. Understanding patterns of inequal... more

Download (186)

View PDF (218)

Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021

World Health Organization WHO (2022) C_WHO

27 September 2022 These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.

External Link

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

GBD2019 Dementia Forecasting Coolaborators (2022) CC

Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8 Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform nati... more

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) recommended

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
recommended